The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index; none of the 28 sources its claims cite is checked for support yet.
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder
Open accessAbstract
Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion), an oral N-methyl-D-aspartate (NMDA) receptor antagonist and σ1 receptor agonist, in the treatment of major depressive disorder (MDD). Methods: This double-blind, phase 3 trial, was conducted between June 2019 and December 2019. Patients with a DSM-5 diagnosis of MDD were randomized in a 1:1 ratio to receive dextromethorphan-bupropion (45 mg-105 mg tablet) or placebo, orally (once daily for days 1–3, twice daily thereafter) for 6 weeks. The primary endpoint was the change from baseline to week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Other efficacy endpoints and variables included MADRS changes from baseline at week 1 and 2, clinical remission (MADRS score ≤ 10), clinical response (≥ 50% reduction in MADRS score from baseline), clinician- and patient-rated global assessments, Quick Inventory of Depressive Symptomatology-Self-Rated, Sheehan Disability Scale, and quality of life measures. Results: A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo. Mean baseline MADRS total scores were 33.6 and 33.2 in the dextromethorphan-bupropion and placebo groups, respectively. The least-squares mean change from baseline to week 6 in MADRS total score was −15.9 points in the dextromethorphan-bupropion group and −12.0 points in the placebo group (least-squares mean difference, −3.87; 95% confidence interval , −1.39 to −6.36; P = .002). Dextromethorphan-bupropion was superior to placebo for MADRS improvement at all time points including week 1 (P = .007) and week 2 (P < .001). Remission was achieved by 39.5% of patients with dextromethorphan-bupropion versus 17.3% with placebo (treatment difference, 22.2; 95% CI, 11.7 to 32.7; P < .001), and clinical response by 54.0% versus 34.0%, respectively (treatment difference, 20.0%; 95% CI, 8.4%, 31.6%; P < .001), at week 6. Results for most secondary endpoints were significantly better with dextromethorphan-bupropion than with placebo at almost all time points (eg, CGI-S least-squares mean difference at week 6, −0.48; 95% CI, −0.48 to −0.79; P = .002). The most common adverse events in the dextromethorphan-bupropion group were dizziness, nausea, headache, somnolence, and dry mouth. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction. Conclusions: In this phase 3 trial in patients with MDD, treatment with dextromethorphan-bupropion (AXS-05) resulted in significant improvements in depressive symptoms compared to placebo starting 1 week after treatment initiation and was generally well tolerated. Trial Registration: ClinicalTrials.gov Identifier: NCT04019704
Overview
CoChat Summary
TL;DR
In this phase 3 randomized trial, AXS-05 (dextromethorphan-bupropion) produced significantly greater reduction in MADRS total score than placebo at week 6 in patients with major depressive disorder, with separation from placebo by week 1. AXS-05 was generally well tolerated, with dizziness, nausea, headache, somnolence, and dry mouth as the most common adverse events.
Key findings
- Primary endpoint: least-squares mean change from baseline to week 6 in MADRS total score was −15.9 points with dextromethorphan-bupropion vs −12.0 with placebo (least-squares mean difference, −3.87; 95% CI, −1.39 to −6.36; P = .002).
- Early efficacy: MADRS change at week 1 was −7.20 vs −4.97 (difference, −2.23; 95% CI, −0.60 to −3.86; P = .007), and at week 2 was −11.09 vs −7.66 (difference, −3.44; 95% CI, −1.40 to −5.47; P < .001).
- At week 6, remission (MADRS ≤ 10) was 39.5% vs 17.3% (treatment difference, 22.2%; 95% CI, 11.7%–32.7%; P < .001), and clinical response (≥ 50% MADRS reduction) was 54.0% vs 34.0% (treatment difference, 20.0%; 95% CI, 8.4%–31.6%; P < .001).
- Safety: adverse events occurred in 61.7% vs 45.1%; adverse events leading to discontinuation occurred in 6.2% vs 0.6%. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction, and there were no suicide-related adverse events or suicidal behaviors on the C-SSRS.
Methods
- Phase 3, randomized, double-blind, placebo-controlled, 6-week trial conducted at 40 US centers from June 2019 to December 2019; 327 patients were randomized 1:1 to dextromethorphan-bupropion 45 mg–105 mg or placebo (once daily for days 1–3, twice daily thereafter). The modified intent-to-treat population included 156 patients in the dextromethorphan-bupropion group and 162 in the placebo group.
- Patients were men or women aged 18–65 years with DSM-5 MDD, a major depressive episode of at least 4 weeks, MADRS total score ≥ 25, and CGI-S score ≥ 4. Key exclusions included bipolar disorder, psychotic disorder, panic disorder, obsessive-compulsive disorder, treatment-resistant depression, alcohol/substance use disorder within the past year, clinically significant suicide risk, and seizure disorder history.
- The primary endpoint was change from baseline to week 6 in MADRS total score, analyzed using a mixed model for repeated measures/ANCOVA with treatment, week, treatment-by-week interaction, baseline value as covariate, and patient as random effect. Percentage endpoints were analyzed via χ² tests; key secondary endpoints used hierarchical testing; no imputation was used for primary or secondary endpoints, with sensitivity analyses by random replacement and tipping point methods.
Limitations
- Stated in the paper: exclusions of patients with psychotic or other psychiatric disorders, alcohol/substance use disorders, clinically significant suicide risk, or significant medical comorbidities may limit generalizability; treatment at experienced trial sites by specialized clinicians under a protocol with frequent assessments may not reflect general practice; dropout was 24.1% in the dextromethorphan-bupropion group vs 10.4% with placebo; multiplicity adjustments were applied only to key secondary endpoints; and trial duration was limited to 6 weeks.
- Evident from the text: the sponsor designed the protocol, oversaw study conduct, analyzed and interpreted data, authored the manuscript, and had final decision to submit it; baseline sex distribution differed between groups (39.1% male with dextromethorphan-bupropion vs 27.8% with placebo; P = .033).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 18 Not checked · 70 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo.”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Abstract
plainn = 327- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Dextromethorphan-bupropion significantly reduced MADRS total scores compared to placebo at all time points assessed (Figure 2).”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Efficacy
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The medication-placebo difference for dextromethorphan-bupropion on the change in MADRS was substantial at all time points, being approximately 2-3 points at weeks 1 and 2 and increasing to approximately 4-5 points at weeks 4 and 6.”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > DISCUSSION
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients in whom adverse events occurred during the treatment period was 61.7% in the dextromethorphan-bupropion group and 45.1% in the placebo group.”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Dextromethorphanbupropion was not associated with weight gain or increased sexual dysfunction.”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > DISCUSSION
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 88 claims and every source verdict.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although it does not act as rapidly as ketamine, Auvelity demonstrated a significant difference from placebo at one week and up until six weeks (n = 327) [186]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Changes in Montgomery–Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remission (MADRS total score < 10) was achieved by 39.5% of patients in the dextromethorphan-bupropion group versus 17.3% in the placebo group at week 6”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [18]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > DISCUSSION
“At week 6, the percentage of patients achieving remission was 39.5% in the dextromethorphanbupropion group compared to 17.3% in the placebo group (P = .004).”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Efficacy
“At week 6, the percentage of patients achieving remission was 39.5% in the dextromethorphanbupropion group and 17.3% in the placebo group (treatment difference, 22.2%; 95% CI, 11.7%-32.7%;P < .001).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The least-squares mean change from baseline to week 6 in CGI-S score was -1.69 points in the dextromethorphan-bupropion group and -1.29 points in the placebo group (least-squares mean difference, -0.48; 95% CI, -0.48 to -0.79; P = .002).”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Efficacy
Reported -0.48 · recomputed -0.4
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Efficacy
“least-squares mean difference, -0.48; 95% CI, -0.48 to -0.79; P = .002”
§ Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) > Safety
“CGI-S score change from baseline Week 6 LS mean (SE) -1.7 (0.1) -1.2 (0.1) -0.5 (-0.2 to -0.8) .002”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
(1993) · PubMed · Cited by 1,900
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Self-citationFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Self-citationFeyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421
Research works printed but not linked: 10
- P u M e d C r o s s R e f 4. Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017;152:21-37. · DOI · Paper page
- P u b M e d C r o s s R e f 10. Fava M, Freeman MP, Flynn M, et al. Double- blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25(7):1592-1603. · DOI · Paper page
- P u b M e d C r o s s R e f 12. Nguyen L, Robson MJ, Healy JR, et al. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9(2):e89985. P u b M e d C r o s s R e f 13. Niciu MJ, Ionescu DF, Richards EM, et al. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121(8):907-924. · DOI · Paper page
- P u b M e d C r o s s R e f 22. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. · DOI
- P u b M e d C r o s s R e f 26. Bech P. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci. 2006;8(2):207-215. · DOI
- P u M e d C r o s s R e f 28. Khan A, Bhat A, Kolts R, et al. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther. 2010;16(4):217-226. · DOI · Paper page
- P u b M e d C r o s s R e f 29. Keefe RS, Kraemer HC, Epstein RS, et al. Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innov Clin Neurosci. 2013;10(suppl A):4S-19S. P u b M e d 30. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. · DOI · Paper page
- P u b M e d C r o s s R e f 31. Cheung CP, Thiyagarajah MT, Abraha HY, et al. The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: an examination of the Nocebo Effect. J Affect Disord. 2021;280(Pt A):140-147. · DOI · Paper page
- P u b M e d C r o s s R e f 32. Schalkwijk S, Undurraga J, Tondo L, et al. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. Int J Neuropsychopharmacol. 2014;17(8):1343-1352. · DOI
- P u M e d C r o s s R e f · DOI · Paper page
Cited by
Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb
Ma, S., Chen, M., Jiang, Y., Xiang, X., Wang, S., Wu, Z., Li, S., Cui, Y., Wang, J., Zhu, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06624-1 · Cited by 204
“However, this notion was directly challenged by a recent phase 3 clinical trial demonstrating that in conjunction with a compound to slow down its metabolism, AXS-05, another pore-trapping-type NMDAR inhibitor, effectively improved the condition of patients with depression 51 .”
BackgroundCutler, A., Mattingly, G., & Maletić, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 130
Psychotropic Drug–Related Weight Gain and Its Treatment
McIntyre, R. S., Kwan, A. T. H., Rosenblat, J. D., Teopiz, K. M., & Mansur, R. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230922 · Cited by 134
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“Although it does not act as rapidly as ketamine, Auvelity demonstrated a signi fi cant difference from placebo at one week and up until six weeks ( n = 327) [186].”
BackgroundEgunlusi, A. O., & Joubert, J. (2024) · Pharmaceuticals · doi:10.3390/ph17050639 · Cited by 101
Metadata
- Authors
- Iosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H.
- Affiliations
- Axsome Therapeutics (United States) (US)
- Corresponding author
- Jones, Amanda
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2022-05-30
- Volume
- 83
- Issue
- 4
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W4281570368
- Cited by
- 135
- References
- 23
- Citations by year
- 2026: 27 · 2025: 36 · 2024: 34 · 2023: 31 · 2022: 7
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, NMDA receptor antagonists, sigma-1 receptor agonist, glutamatergic neurotransmission, antidepressant efficacy, antidepressant safety, clinical remission, quality of life, disability, adverse events, drug tolerability, rapid antidepressant response
- MeSH terms
- Major Depressive Disorder, Dextromethorphan, Double-Blind Method, Humans, Quality of Life, Bupropion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder. https://app.cochat.ai/papers/10.4088/jcp.21m14345
- The paper
- Iosifescu, D. V., Jones, A., O’Gorman, C., Streicher, C., Feliz, S., Fava, M., & Tabuteau, H. (2022). Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.21m14345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.